Digital GLP-1 therapy program reports weight loss in 8,127 women

This UK observational study assessed outcomes among 8,127 women who initiated GLP-1 receptor agonist therapy through a digital care program. The program included mandatory biochemical monitoring, weekly video-supported follow-up and clinician-guided dose titration; 99.8% of participants received tirzepatide. Outcomes included weight change, biomarkers and retention over six months.

Mean weight loss was 16.1 kg, or 15.5% of baseline weight (95% CI 15.9–16.2 kg). At least 10% weight loss was achieved by 83.1% of participants, and 22.4% lost at least 20%. Among participants with paired biomarker data, mean HbA1c fell by 3.3 mmol/mol. Lipid measures also improved. Six-month retention was 91.4%, and no serious treatment-related adverse events were reported.

The findings provide prospective real-world evidence that this structured digital model can deliver obesity pharmacotherapy at scale in a female population. However, the observational design, lack of a comparator, self-pay setting and six-month follow-up limit conclusions about comparative effectiveness, longer-term outcomes and applicability to other populations or care settings.